

Clinical Trials Summary for out of hours Important Reference

Acronym study title	COLUMBUS AD - EORTC
Study Details	W00090GE303 / EORTC-2139-MG Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C <i>BRAF</i> V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group.
Principal Investigator PI Sub PI's	Dr Kellati Prasad PI Dr Dinakshi Shah Sub Investigator Dr Ruth Board Sub Investigator
Research Nurse Team	Carolyn Hatch
Drug therapy	Adjuvant Encorafenib 450 mg OD and Binimetinib 45 mg BD v placebo, orally for 1 year. Triple blinded.
In the event that a patient calls this hotline for advise	Please inform Research team on 01772 522801 if patients develop toxicity or is admitted to hospital.